Good morning,
Welcome to today’s edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
Short update from me.
Just arrived at the airport in Brisbane, going to spend the day with Bioxyne (ASX: BXN) and visit their cannabis packing and GMP facilities.
Bioxyne is a GMP manufacturer of medical-grade cannabis (and also produces medical-grade MDMA and Psilocybin).
The company has been on a big run over the last few months, posting impressive revenue growth from $9.4 million in FY24 and is on track for $64 million this financial year.
(and that’s on the low side of guidance)
One of my readers, Trader Matty, is a big fan of the stock.
So I’ve flown up to the Sunny State to answer one question:
How do you win at the cannabis game?
I’ll have my full write-up as part of the Biotech 165 Challenge next week.
Also, a shoutout to Queensland Pete, who sat next to me on the flight and gave me some really good advice after I told him I had just started venturing out on my own.
You can fail 100 times, but you only need to succeed just once.
On that note, let’s dive in…
The Pulse Check
Orthocell’s (ASX: OCC) Remplir™ nerve repair device has been successfully used in 23 surgeries on injured soldiers in Ukraine. (OCC)
🪑 Did someone say military applications?
Preclinical work shows that Biotron’s (ASX: BIT) anti-viral treatment is effective against Hepatitis Delta Virus. (BIT)
🪑 Milestone ticked. More importantly, BIT said that it would submit an application to the EMA ‘ahead of schedule’ for advice on the regulatory pathway forward for its newly acquired SedRx product.
The outcome of this advice will set up the company’s catalysts for the near term.
Rhythm Biosciences (ASX: RHY) has activated 38 blood collection sites in partnership with 4Cyte Pathology for its colorectal cancer screening test. (RHY)
Firebrick Pharma (ASX: FRE) has secured a patent in the Philippines for its nasal spray technology to reduce SARS-CoV-2 viral load. (FRE)
🪑 2021 is calling, and it wants its announcement back.
See you all tomorrow,
The Armchair Analyst.
